STOCK TITAN

Organigram to Report Second Quarter 2022 Results on April 12, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Organigram Holdings Inc. (NASDAQ: OGI), a top cannabis producer, will report its second quarter 2022 earnings results on April 12, 2022, prior to market opening. The Company will hold a conference call on the same day at 8:00 am ET to discuss the results. Interested parties can register for the call through a provided link and also access a webcast of the discussion. A replay will be available within 24 hours after the call concludes. Organigram focuses on producing quality cannabis products and expanding its international presence.

Positive
  • None.
Negative
  • None.

TORONTO--(BUSINESS WIRE)-- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter 2022 ended February 28, 2022 on Tuesday, April 12, 2022 before market open.

The Company will host a conference call to discuss its results with details as follows:

Date: April 12, 2022
Time: 8:00 am Eastern Time

To register for the conference call, please use this link:
https://conferencingportals.com/event/RUyBPhzX

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:
https://events.q4inc.com/attendee/457187993

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include: Organigram Inc. and Laurentian Organic Inc., licensed producers of cannabis and cannabis-derived products in Canada, and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews in Canada. Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include scheduling changes and factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For media inquiries:

Megan McCrae

Senior Vice-President, Marketing and

Communications

megan.mccrae@organigram.ca

For investor inquiries:

investors@organigram.ca

Source: Organigram Holdings Inc.

FAQ

When will Organigram Holdings report its second quarter 2022 earnings?

Organigram Holdings will report its second quarter 2022 earnings on April 12, 2022.

What time will the Organigram conference call take place?

The Organigram conference call will take place at 8:00 am Eastern Time on April 12, 2022.

How can I register for the Organigram earnings call?

You can register for the Organigram earnings call by following the link provided in their press release.

Where can I access the webcast of the Organigram earnings call?

The webcast of the Organigram earnings call will be available through a link in their press release.

Will there be a replay of the Organigram earnings call?

Yes, a replay of the Organigram earnings call will be available within 24 hours after the call.

Organigram Holdings Inc. Common Shares

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Stock Data

166.12M
75.87M
31.32%
9.73%
2.11%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto